{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-080546","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2024-07-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.402829+00:00","generated_at":"2026-05-31T23:47:53.872938+00:00","sec_items":["1.01","2.03"],"event_type":"debt","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Olema Pharmaceuticals amends loan facility, ups potential borrowing to $100M, extends maturity to 2028","bullets":["Borrowing capacity increased from $50M to up to $100M with $25M immediately available.","Additional $25M available upon milestone: execution of first line pivotal Phase 3 trial of palazestrant with ribociclib.","Further $50M may be available at bank's discretion; maturity extended 11 months to July 1, 2028.","No funds drawn under the loan agreement to date."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-080546","json":"https://secwatch.observer/filing/0000950170-24-080546.json","markdown":"https://secwatch.observer/filing/0000950170-24-080546.md","text":"https://secwatch.observer/filing/0000950170-24-080546.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000095017024080546/0000950170-24-080546-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000095017024080546/olma-20240628.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T23:47:53.872938+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}